Quest Diagnostics Incorporated
DGX US
DGX USQuest Diagnostics Incorporated
United States Composite137.55
Company Description
- CEO
- Mr. James E. Davis
- Full Time Employees
- 40,000
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Address
- 500 Plaza Drive Secaucus NJ United States 07094
- IPO Date
- Dec 17, 1996
- Website
- www.questdiagnostics.com
- Business
- Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Company News
Earnings Preview: Quest Diagnostics (DGX) Q1 Earnings Expected to Decline
Earnings Preview: Quest Diagnostics (DGX) Q1 Earnings Expected to Decline
Quest Diagnostics (DGX) to Post Q1 Earnings: What's in Store?
Quest Diagnostics (DGX) to Post Q1 Earnings: What's in Store?
Q4HE Initiative Recognized for Efforts To Reduce Health Disparities
Myriad Genetics (MYGN) Announces Favorable Research Results
Myriad Genetics (MYGN) Announces Favorable Research Results
My Quest Story - Jessica Clow
Quest Diagnostics' (NYSE:DGX) investors will be pleased with their respectable 62% return over the last five years
Quest Diagnostics Inc's Dividend Analysis
Quest Diagnostics (DGX) Collaborates With Broad Clinical Labs
Quest Diagnostics and Broad Clinical Labs to Evaluate Whole Genome Sequencing as First-Line Genetic Test for Developmental Delay
My Quest Story - Pauline Chaves
She Is Not Skipping a Beat, and Patients Are Noticing
Study in Frontiers in Neurology Affirms Amyloid Blood Test Can Help Identify Patients Who May Forgo Imaging Evaluation for Alzheimer's Disease
Labcorp (LH) Boost Diagnostics Suite With New Biomarker Test
My Quest Story - Eddy Hurst
Quest Diagnostics to Release First Quarter 2024 Financial Results on April 23, 2024
Quest Diagnostics (NYSE:DGX) Has Announced That It Will Be Increasing Its Dividend To $0.75
Quest Colleague Is Exhibiting Care for Every Patient in Her Chair